Affiliations 

  • 1 Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203,USA
  • 2 Department of Epidemiology, Shanghai Cancer Institute, Shanghai200032, China
  • 3 Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China
  • 4 Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
  • 5 Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK
  • 6 International Agency for Research on Cancer, 69372 Lyon CEDEX 08, France
  • 7 Department of Surgery, Changhua Christian Hospital,Changhua City 50006,Taiwan
  • 8 Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea
  • 9 Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117549, Singapore
  • 10 Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan
  • 11 Division of Health Sciences, Warwick Medical School, Warwick University, Coventry CV4 7AL, UK
  • 12 Division of Molecular Medicine, Aichi Cancer CenterResearch Institute, Nagoya 464-8681, Japan
  • 13 National Cancer Institute,Bangkok 10400, Thailand
  • 14 Taiwan Biobank, Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan
  • 15 Cancer Research Initiatives Foundation, Subang Jaya, Selangor 47500, Malaysia
  • 16 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles CA 90032, USA
  • 17 Breast Cancer Research Unit, Cancer Research Institute, University Malaya Medical Centre, Kuala Lumpur 59100, Malaysia and
Carcinogenesis, 2017 May 01;38(5):511-518.
PMID: 28419251 DOI: 10.1093/carcin/bgx010

Abstract

Over the past 20 years, high-penetrance pathogenic mutations in genes BRCA1, BRCA2, TP53, PTEN, STK11 and CDH1 and moderate-penetrance mutations in genes CHEK2, ATM, BRIP1, PALB2, RAD51C, RAD50 and NBN have been identified for breast cancer. In this study, we investigated whether there are additional variants in these 13 genes associated with breast cancer among women of Asian ancestry. We analyzed up to 654 single nucleotide polymorphisms (SNPs) from 6269 cases and 6624 controls of Asian descent included in the Breast Cancer Association Consortium (BCAC), and up to 236 SNPs from 5794 cases and 5529 controls included in the Shanghai Breast Cancer Genetics Study (SBCGS). We found three missense variants with minor allele frequency (MAF) <0.05: rs80358978 (Gly2508Ser), rs80359065 (Lys2729Asn) and rs11571653 (Met784Val) in the BRCA2 gene, showing statistically significant associations with breast cancer risk, with P-values of 1.2 × 10-4, 1.0 × 10-3 and 5.0 × 10-3, respectively. In addition, we found four low-frequency variants (rs8176085, rs799923, rs8176173 and rs8176258) in the BRCA1 gene, one common variant in the CHEK2 gene (rs9620817), and one common variant in the PALB2 gene (rs13330119) associated with breast cancer risk at P < 0.01. Our study identified several new risk variants in BRCA1, BRCA2, CHEK2, and PALB2 genes in relation to breast cancer risk in Asian women. These results provide further insights that, in addition to the high/moderate penetrance mutations, other low-penetrance variants in these genes may also contribute to breast cancer risk.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.